iNtRON Biotechnology Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
73
- Stock Symbol
-
048530
- Investments
-
3
- Share Price
-
$1.92
- (As of Thursday Closing)
iNtRON Biotechnology General Information
Description
iNtRON Biotechnology Inc is a Korea-based biotechnology firm focused on the research, development, and commercialization of biopharmaceuticals and molecular diagnostics. Its core business includes developing bacteriophage- and endolysin-based therapeutic platforms for infectious diseases, immune disorders, microbiome-related diseases, vaccines, and oncology applications. It also develops and manufactures PCR/qPCR-based molecular diagnostic kits for human and animal infectious diseases, supported by GMP-certified automated production facilities. In addition, the company pursues strategic partnerships and equity investments to expand its biotechnology ecosystem and commercialize technologies derived from its drug development programs.
Contact Information
Website
www.intron.co.krCorporate Office
- 137, Sagimakgol-ro, Jungwon-gu
- Sangdaewon-Dong Jungang Induspia 5th
- Seongnam, Gyeonggi 13202
- South Korea
Corporate Office
- 137, Sagimakgol-ro, Jungwon-gu
- Sangdaewon-Dong Jungang Induspia 5th
- Seongnam, Gyeonggi 13202
- South Korea
iNtRON Biotechnology Stock Performance
As of 12-Nov-2026, iNtRON Biotechnology’s stock price is $1.92. Its current market cap is $59.3M with 30.9M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.92 | $1.96 | $1.50 - $4.79 | $59.3M | 30.9M | 220K | -$0.20 |
iNtRON Biotechnology Financials Summary
As of 31-Dec-2025, iNtRON Biotechnology has a trailing 12-month revenue of $4.03M.
|
In Thousands, USD |
TTM 31-Dec-2025 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 47,168 | 47,168 | 86,605 | 173,417 |
| Revenue | 4,034 | 4,034 | 4,704 | 7,331 |
| EBITDA | (5,542) | (5,542) | (1,661) | (6,519) |
| Net Income | (6,295) | (6,295) | (1,899) | (7,416) |
| Total Assets | 51,612 | 51,612 | 58,640 | 76,524 |
| Total Debt | 2,329 | 2,329 | 845 | 313 |
iNtRON Biotechnology Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
iNtRON Biotechnology Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
iNtRON Biotechnology Patents
iNtRON Biotechnology Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024128526-A1 | Antimicrobial protein cdl2200 having lytic activity to clostridioides difficile | Inactive | 15-Dec-2022 | ||
| US-11970700-B1 | Genetic element e3 for enhanced intracellular expression of target protein encoded in rna therapeutics | Active | 13-Dec-2022 | ||
| EP-4563590-A1 | Antibacterial protein composition for treatment of bovine mastitis | Pending | 26-Jul-2022 | ||
| EP-4563590-A4 | Antibacterial protein composition for treatment of bovine mastitis | Pending | 26-Jul-2022 | ||
| US-20260258093-A1 | Antibacterial protein composition for treatment of bovine mastitis | Pending | 26-Jul-2022 | C07K14/195 |
iNtRON Biotechnology Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
iNtRON Biotechnology Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
iNtRON Biotechnology Investments (3)
iNtRON Biotechnology’s most recent deal was a Later Stage VC with LISCure Biosciences for . The deal was made on 19-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| LISCure Biosciences | 19-Dec-2024 | Later Stage VC | Drug Discovery | ||
| Immunique | 05-Oct-2021 | Seed Round | Drug Discovery | ||
| LISCure Biosciences | 01-Oct-2020 | Early Stage VC | Drug Discovery |
iNtRON Biotechnology ESG
Risk Overview
Risk Rating
Updated July, 31, 2023
28.63 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,766
Rank
Percentile
Pharmaceuticals
Industry
of 891
Rank
Percentile
Biotechnology
Subindustry
of 394
Rank
Percentile
iNtRON Biotechnology FAQs
-
When was iNtRON Biotechnology founded?
iNtRON Biotechnology was founded in 1999.
-
Where is iNtRON Biotechnology headquartered?
iNtRON Biotechnology is headquartered in Seongnam, South Korea.
-
What is the size of iNtRON Biotechnology?
iNtRON Biotechnology has 73 total employees.
-
What industry is iNtRON Biotechnology in?
iNtRON Biotechnology’s primary industry is Drug Discovery.
-
Is iNtRON Biotechnology a private or public company?
iNtRON Biotechnology is a Public company.
-
What is iNtRON Biotechnology’s stock symbol?
The ticker symbol for iNtRON Biotechnology is 048530.
-
What is the current stock price of iNtRON Biotechnology?
As of 12-Nov-2026 the stock price of iNtRON Biotechnology is $1.92.
-
What is the current market cap of iNtRON Biotechnology?
The current market capitalization of iNtRON Biotechnology is $59.3M.
-
What is iNtRON Biotechnology’s current revenue?
The trailing twelve month revenue for iNtRON Biotechnology is $4.03M.
-
What is iNtRON Biotechnology’s annual earnings per share (EPS)?
iNtRON Biotechnology’s EPS for 12 months was -$0.20.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
